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Pharmacometabolomic mapping of early biochemical
changes induced by sertraline and placebo
R Kaddurah-Daouk1, MB Bogdanov2, WR Wikoff3, H Zhu1, SH Boyle1, E Churchill1, Z Wang4, AJ Rush5, RR Krishnan1,5,
E Pickering6, M Delnomdedieu7 and O Fiehn3
In this study, we characterized early biochemical changes associated with sertraline and placebo administration and changes
associated with a reduction in depressive symptoms in patients with major depressive disorder (MDD). MDD patients received
sertraline or placebo in a double-blind 4-week trial; baseline, 1 week, and 4 weeks serum samples were profiled using a gas
chromatography time of flight mass spectrometry metabolomics platform. Intermediates of TCA and urea cycles, fatty acids and
intermediates of lipid biosynthesis, amino acids, sugars and gut-derived metabolites were changed after 1 and 4 weeks of
treatment. Some of the changes were common to the sertraline- and placebo-treated groups. Changes after 4 weeks of treatment
in both groups were more extensive. Pathway analysis in the sertraline group suggested an effect of drug on ABC and solute
transporters, fatty acid receptors and transporters, G signaling molecules and regulation of lipid metabolism. Correlation
between biochemical changes and treatment outcomes in the sertraline group suggested a strong association with changes in
levels of branched chain amino acids (BCAAs), lower BCAAs levels correlated with better treatment outcomes; pathway analysis
in this group revealed that methionine and tyrosine correlated with BCAAs. Lower levels of lactic acid, higher levels of TCA/urea
cycle intermediates, and 3-hydroxybutanoic acid correlated with better treatment outcomes in placebo group. Results of this
study indicate that biochemical changes induced by drug continue to evolve over 4 weeks of treatment and that might explain
partially delayed response. Response to drug and response to placebo share common pathways but some pathways are more
affected by drug treatment. BCAAs seem to be implicated in mechanisms of recovery from a depressed state following sertraline
treatment.
Translational Psychiatry (2013) 3, e223; doi:10.1038/tp.2012.142; published online 22 January 2013
Introduction
Major depressive disorder (MDD) is a common and potentially
life-threatening psychiatric illness that is a significant cause of
disability worldwide.1 Selective serotonin (5-HT) reuptake
inhibitors (SSRIs) are the major class of antidepressants for
the treatment of MDD. Antidepressant effects of SSRIs result
from inhibition of presynaptic 5-HT transporter, followed
by changes in 5-HT neurotransmission and secondary
changes in other neurotransmitter systems, such as catecho-
lamines,2–5 neurotransmitter amino acids6–10 and acetylcho-
line.11 It was shown that SSRIs induce delayed transcriptional
and translational changes that mediate molecular and cellular
neuroplasticity.12–14 Different antidepressants, including
SSRIs, following their chronic administration have been found
to increase biomarkers for energy metabolism.15–18
The onset of antidepressant therapeutic action typically
does not occur until at least 2–4 weeks of treatment;
mechanisms underlying this delayed effect of antidepressants
remain largely unknown and the biochemical changes that
happen over the first 4 weeks that lead to therapeutic benefit
are not well defined. Response to current therapies in treating
MDD varies considerably, with 40%of patients not responding
and 60% not remitting after an initial trial of therapy.19 Both the
delayed onset of antidepressant therapeutic action and the
variability in the response prevent clinicians from predicting
whether an antidepressant is going to work for a particular
patient. The detailed molecular mechanisms underlying
variation in treatment response in depression and the genetic
and biochemical basis remain unknown although numerous
studies implicate the norepinephrine and 5-HT systems.20–23
The placebo effect adds complexity, as 30–40% of MDD
patients respond to placebo through mechanisms that are not
yet understood.24,25 Further insights into the mechanisms of
response to placebo vs response to medications are needed
and an ability to identify early on who might be a responder to
placebo can stream line clinical trials. Development of
biomarkers that can predict early on no response should
have great clinical utility.
Metabolomics enables the identification and quantification
of hundreds to thousands of compounds that can report on
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changes in biochemical pathways and should provide novel
insights into the complex metabolic mechanisms of disease
and drug effects.26,27 Metabolomics provides powerful tools
for characterization of complex phenotypes involving endo-
genous and exogenous mechanisms and for studies of
complex diseases, such as depression. We have started to
apply metabolomics tools to map global plasma biochemical
changes in depressive subjects in remission and in mechan-
isms involved in response to SSRIs. In prior studies we
identified perturbations in lipid metabolism, dicarboxylic fatty
acids, branched chain and other amino acids, including
GABA, as well as in ketone bodies in plasma of subjects with
MDD.28,29 In a study by Ji et al.,30 we used a pharmacome-
tabolomics-informed pharmacogenomic research strategy
and identified that glycine and a single-nucleotide polymorph-
ism (SNP) in the glycine dehydrogenase gene were asso-
ciated with response to escitalopram treatment. Merging
pharmacometabolomics with pharmacogenomics using ‘1000
Genomes’ SNP imputation, we provided additional insights
about selective serotonin reuptake inhibitor response.31 We
also demonstrated that metabolic profiles prior to treatment
could help distinguish responders from non-responders to
sertraline and placebo.32
In this current study, a hypothesis-generating metabolo-
mics approach was used to map global biochemical changes
induced by 1 week and 4 weeks treatment with sertraline and
placebo. We also correlated biochemical changes and
treatment outcomes at 1 and 4 weeks as a first step towards
determining which biochemical changes could be associated
with the delayed response to sertraline treatment.
Methods
Study design and patients. Study participants were out-
patients, 18–65 years of age, from a randomized, double-
blind, flexible dosing, placebo-controlled study performed at
12 clinical sites. Patients had a primary diagnosis of non-
psychotic MDD by DSM-IV criteria, with symptoms of
depression present for at least 1 month prior to screening,
and a total baseline score 422 on the 17-item Hamilton
Rating Scale for Depression (HAMD17)
30 at screening. The
full exclusion criteria for patients enrolled in the study was
reported before.32 Patients were randomized to treatment
(oral administration) with either sertraline or placebo at a ratio
of 1:1. Sertraline dosing was started at 50mg per day at
baseline (week 0), with dose increased up to 100mg per day
at week 1 and up to 150mg per day at week 2, as seen
needed by the treating clinician. The primary outcome
measure was the HAMD17 score. HAMD17 scores were
determined and serum samples were collected at baseline
(before treatment started), 1 week and at 4 weeks after
treatment; the samples were collected from fasting subjects.
A complete list of the inclusion and exclusion criteria used in
this study, subjects medications, have been described in our
previous report.32 Briefly, no psychotropic medications were
used by the participants. The study protocol was developed
in accordance with the principles of the Declaration of
Helsinki. All patients provided written informed consent.
The study was sponsored and monitored by Pfizer (Groton,
CT, USA). Each site’s IRB approved and oversaw the study.
GC-TOF mass spectrometry. Data were collected as
described in Trupp et al.33 Briefly, the study design was
entered into the SetupX database.34 Samples were ali-
quotted and maintained at  80 1C until use, at which point
30 ml of samples were extracted and derivatized with
methoxyamine and MSTFA to trimethylsilation. Fatty acid
methyl esters internal standards were included in the sample.
One microliter of sample was injected using a Gerstel liner
exchange system onto an Agilent 6890 gas chromatograph
(Santa Clara, CA, USA) interfaced to a Leco Pegasus IV time
of flight mass (TOF) spectrometer. Data were processed
using BinBase35 and compound spectra and retention times
were matched against the Fiehn laboratory library or
NIST05.36 Intensities from all identified metabolites were
summed and this value was used for data normalization.
These data were used for statistical analysis.
Statistical methods
Metabolic signatures of sertraline and placebo (univariate
analysis). Paired t-tests were used to determine which
metabolites changed significantly from baseline to week 1
and to week 4. These analyses were conducted separately
for the sertraline and placebo groups. A significant t-test
indicates that a metabolite is changing differently in the two
groups. To determine which metabolites changed differently
between the sertraline and placebo groups, we compared 1-
week change scores and 4-week change scores between the
two groups using t-tests for independent groups. Metabolite
values were log transformed before data analysis.
Q-values37 were calculated to control for false discovery rate.
Correlation with response analysis. Pearson correlation
analysis was used to examine associations of changes in
metabolite levels with concurrent changes in depressive
symptoms. Analyses were conducted separately for 1- and
4-week change. Correlations of the sertraline group and
placebo group were compared using the two-sample Z-test
after hyperbolic tangent transformation. For these tests,
Q-values37 were calculated for controlling the false discovery
rate.
Response-pathway oriented analysis. After testing the
marginal effects of metabolites, we then aimed to identify sets
of metabolites with group effects on the drug response through
the following steps. First, an individually significant metabolite
was chosen based on the aforementioned marginal correlation
analysis; second, a small subset of metabolites of strong
marginal correlations with the preselected metabolite was
identified; third, a principal component regression (PCR)
analysis was used to regress the drug response on several
principal components. These principal components are linear
combinations of the subset of metabolites and therefore
represent the group effect of the subset.
Pathway enrichment and network modeling. Pathways and
networks were analyzed using multiple approaches. Meta-
Mapp38 was used to calculate metabolic networks, which
were displayed using Cytoscape. MetaMapp uses KEGG
reaction pairs to build a metabolic network and then adds
non-mapped compounds via Tanimoto similarity.39
Early biochemical changes induced by sertraline and placebo
R Kaddurah-Daouk et al
2
Translational Psychiatry
Results
Sample characteristics. The sertraline and placebo
groups did not differ significantly in age (44±11.4 years
vs 40±12.7 years, P¼ 0.12), gender (29/43 (69%)
female vs 32/46 (70%) female, P¼ 0.83) or race (34/43
(79%) white vs 34/46 (74%) white, P¼ 0.57). The response
rate was slightly higher for sertraline than for placebo, but
this difference was not statistically significant (26/43 (60%)
vs 23/46 (50%)) responders for sertraline and placebo
groups, respectively.
Metabolic signatures of sertraline after 1 and 4 weeks of
treatment. A GC-TOF metabolomics platform was used to
semiquantitatively measure 348 compounds in patient
serum. Of these, 143 were known compounds, 17 com-
pounds were identified by spectral matching to the NIST
library and 188 were unknown.
One-week treatment with sertraline. Several metabolites
were changed following 1 week of treatment with sertraline;
they included intermediates of TCA cycle, sugars and
metabolites involved in fatty acid biosynthesis
(Supplementary Table 1). All metabolites except glycerol
showed an increase in concentration over this period.
However, with Q-value cutoff set at 0.1 none of these
changes was found to be significant. A metabolic network
reconstruction highlighting the metabolites that changed after
1 week of sertraline is shown in Figure 1a.
Four-week treatment with sertraline. Biochemical changes
following 4-week treatment with sertraline were far more
extensive than changes seen after 1 week of treatment
(Table 1). Prominent effects were found on levels of fatty
acids (linoleic, palmitic, arachidonic, oleic, palmitoleic and
heptadecanoic acids all showed decreases) and glycerol, as
well as changes in metabolites within the TCA and urea
cycles (decreases in ornithine, citrulline and increase in
aconitic acid). Other changes included metabolites from the
purine pathway (xanthine decreased), one carbon metabo-
lism (cysteine increased), tryptophan (5-methoxytryptamine
decreased and indole-3-acetic acid increased) and a ketone
body (3-hydroxybutanoic acid decreased). With Q-values
cutoff controlled at 0.1, significant changes were decreased
levels of linoleic, arachidonic and palmitic acids, and of
ornithine and glycerol. A metabolic network reconstruction
that highlights the metabolites changed after 4-week treat-
ment with sertraline is shown in Figure 1b.
Pathway enrichment analysis for 4-week treatment with
sertraline is shown in Table 2. Several pathways involved in
signaling were enriched in this analysis including transmem-
brane transporters of small molecules, signaling by GPCR,
fatty acid receptors and transporters.
Metabolic signatures of placebo after 1 and 4 weeks of
treatment
One-week treatment. Metabolites that changed after 1-week
treatment with placebo are shown in Supplementary Table 1.
Changes included amino acids homoserine and aspartate,
one metabolite, xanthine, from the purine pathway, and the
Figure 1 Compounds changing significantly (Po0.05) in the first (a, left top) and fourth (b, right top) week of sertraline treatment up (green) or down (red) are shown as
enlarged nodes. Placebo treatment in the first week (c, left bottom) and fourth week (d, right bottom) is also shown. All compounds that were measured in the experiment are
shown. Gray lines indicate network connections based upon structural similarity and bold blue lines indicate KEGG reaction pairs.
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fatty acids linoleic, oleic and palmitoleic acids. Each
metabolite showed a concentration decrease. However,
similarly to 1-week treatment with sertraline, none of these
changes was significant with Q-value cutoff of 0.1.
Four-week treatment with placebo. Significantly more pro-
found biochemical changes were observed after 4 weeks of
treatment with placebo, compared with 1 week (Table 1).
Reductions were found in levels of fatty acids (linoleic, oleic,
myristic and palmitoleic acids) and glycerol. Other changes
included TCA cycle metabolites (decreased a-ketoglutarate,
and increased glutamine and glutamic acid), amino acids
(decreased homoserine, and increased proline, GABA and
glutamic acid), metabolites linked to one carbon cycle
Table 1 Metabolic changes (Po0.05) after 4-week treatment with sertraline and placebo
Metabolite Sertraline P Q Metabolite Placebo P Q
t-value Percent
change
t-value Percent
change
Linoleic acid  3.791  20.471 0.001 0.036 Elaidic acid 5.259 30.801 5.500E06 0.003
Ornithine  3.788  18.435 0.001 0.036 Fructose 4.213 487.726 1.443E04 0.014
Glycerol  3.597  15.845 0.001 0.052 Hippuric acid 4.389 331.668 8.420E05 0.014
Arachidonic acid isomer  3.306  16.947 0.002 0.088 Linoleic acid 4.175 22.794 1.617E04 0.014
Palmitic acid  3.444  14.788 0.002 0.072 Oleic acid 4.206 21.281 1.472E04 0.014
Arachidonic acid  3.123  15.713 0.004 0.113 Palmitoleic acid 4.520 24.734 5.620E05 0.014
Hippuric acid 3.031 268.553 0.005 0.115 Methionine sulfoxide 3.082 77.910 0.004 0.113
Oleic acid  3.024 0.299 0.005 0.115 Propane-1,3-diol NIST 3.099 11.241 0.004 0.113
Aconitic acid 2.912 26.214 0.006 0.122 a-Ketoglutaric acid 2.997 11.514 0.005 0.115
Cystine 2.667 327.080 0.012 0.161 Palmitic acid 2.978 10.948 0.005 0.115
Palmitoleic acid  2.597 131.426 0.014 0.172 Homoserine 2.879  4.833 0.006 0.122
5-Methoxytryptamine  2.530 425.326 0.016 0.184 Inulobiose 2.835 88.022 0.007 0.127
Xanthine  2.538 8.746 0.016 0.184 Myristic acid 2.843  9.520 0.007 0.127
Myristic acid  2.480 8.007 0.018 0.190 Cytidine-50-diphosphate 2.590 1.726 0.013 0.172
Indole-3-acetate 2.462 21.503 0.019 0.191 Glycerol 2.535  7.201 0.015 0.183
Heptadecanoic acid  2.358 7.089 0.024 0.201 Arabitol 2.479 15.601 0.018 0.190
3-Hydroxybutanoic acid  2.345 33.418 0.025 0.201 Creatinine 2.473 148.690 0.018 0.190
Xylitol 2.197 163.060 0.035 0.228 Hydroxylamine 2.481  8.192 0.018 0.190
Hydroxycarbamate NIST 2.152 298.069 0.039 0.228 2-Deoxytetronic acid 2.434 31.055 0.020 0.193
Asparagines 2.132 53.085 0.040 0.228 Histidine 2.393 59.236 0.022 0.200
Uric acid  2.111 6.143 0.042 0.230 Proline 2.375 30.962 0.023 0.201
Succinic acid  2.067 5.740 0.046 0.235 Glutamine 2.330 82.385 0.025 0.201
Maltose 2.302 171.497 0.027 0.204
3-Hydroxybutanoic acid 2.245 9.976 0.031 0.213
Pseudo uridine 2.158  5.284 0.037 0.228
2-Deoxyerythritol NIST 2.131 133.213 0.039 0.228
GABA 2.133 139.734 0.039 0.228
Glutamic acid 2.098 1264.390 0.042 0.230
Sucrose 2.107 597.169 0.042 0.230
Hydrocinnamic acid 2.089  6.049 0.043 0.230
Xanthine 2.092  5.011 0.043 0.230
Quinic acid 2.070 210.924 0.045 0.233
Oxoproline 2.050  5.221 0.047 0.235
Benzylalcohol 2.043 17.474 0.048 0.235
Significant P-values are in bold.
Table 2 Pathway enrichment analysis of the effect of sertraline exposure from baseline to week 4
Pathway name PT OV Metabolites P Q
Transmembrane transport of small molecules R 9 170 (192) 1.21E 06 1.51E03
Signaling by GPCR R 7 84 (93) 1.30E 06 1.51E03
Signal transduction R 7 89 (98) 1.93E 06 1.51E03
Regulation of lipid metabolism by PPAR-a R 3 5 (5) 3.60E 06 2.12E03
SLC-mediated transmembrane transport R 8 147 (165) 4.85E 06 2.28E03
Free fatty acid receptors R 4 19 (23) 8.34E 06 3.27E03
Transport of fatty acids R 3 9 (9) 2.97E 05 9.96E03
GPCR ligand binding R 5 66 (75) 9.26E 05 0.027
Ga (q) signaling events R 4 38 (43) 1.45E 04 0.038
Nucleotide metabolism W 3 16 (17) 1.91E 04 0.045
Fatty acid, triacylglycerol and ketone body metabolism R 5 83 (89) 2.78E 04 0.059
Glucose homeostasis W 3 21 (21) 4.44E 04 0.087
Arachidonate production from DAG R 2 5 (5) 5.32E 04 0.096
Class A/1 (Rhodopsin-like receptors) R 4 56 (64) 6.62E 04 0.111
Abbreviations: PCR, principal component regression; PT, source of pathway; R, Reactome; W, Wikipathways; OV, number of overlapping metabolites; P, P-value
calculated for metabolites; Q, Q-value calculated for metabolites after correction for FDR.
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(increased creatinine and decreased homoserine)
(Figure 1d). Both xanthine from the purine pathway, and
the ketone body 3-hydroxybutanoic acid were decreased.
With Q-values cutoff controlled at 0.1, significant changes
were found for elaidic, hippuric, linoleic, oleic and palmitoleic
acids and fructose.
Associations of changes in metabolites with treatment
outcomes
One-week treatment with sertraline. The associations
between changes in individual metabolites and treatment
outcome were also examined. Correlations between changes
in individual metabolites and treatment outcome as assessed
using HAMD17 scores are presented in Table 3a. Decrease
in 5-methoxytryptamine (5-MTPM) levels was the most
significant in association with symptoms reduction following
1 week of treatment with sertraline. Symptoms reduction was
also associated with decrease in levels of ribose, trehalose
and cystine. Increases in the levels of arachidonic and a-
ketoglutaric acids were associated with symptoms reduction
after 1-week sertraline treatment.
Four-week treatment with sertraline. After 4 weeks of
sertraline treatment, the most significant changes associated
with symptoms reduction were decreases in the levels of
branched chain amino acids (BCAAs), valine, leucine and
isoleucine (Table 3c). Similarly to 1 week, at 4 weeks of
sertraline treatment symptoms reduction were associated
with increase in levels of cysteine. Improvement of the
symptoms after 4 weeks on sertraline was also associated
with increases in the levels of lactic acid and pseudouridine.
One-week treatment with placebo. After 1 week of treatment
with placebo, decrease in phosphoric acid and increases in
4-hydroxyproline and malate (Table 3b) were associated with
symptoms reduction. Changes in several metabolites within
TCA/urea cycle also correlated with changes in depression
scores.
Four-week treatment with placebo. Changes in lactic acid,
sugars, oxalic acid, ketone body, indole-3-acetic acid, urea
cycle intermediate cirtruline and alanine were associated with
symptoms reduction at 4 weeks of placebo treatment
(Table 3d). In contrast to the sertraline findings, no
association between changes in levels of BCAAs was noted.
Response-pathway oriented analysis. Since valine was
found to be the most significant metabolite showing correla-
tion with response in the sertraline group, we selected a list of
26 metabolites (Supplementary Table 2) marginally corre-
lated with valine in sertraline group including leucine,
isoleucine and tyrosine. A PCR analysis with variable
selection identified four principal components jointly and
significantly associated with drug response. In the first
principal component (Supplementary Table 3), isoleucine,
leucine, methionine, valine and tyrosine possessed the
largest weights. Thus, this metabolite set characterized by
major amino acids explored the possible relationship
between amino acids, their transport and function, and
depression, suggesting that further investigation of amino
acids is warranted in studying biological mechanisms of
sertraline.
Discussion
Recently, we conducted a metabolomics study to determine
whether the baseline metabolic profile (that is, metabotype) of
a patient with MDD would allow a prediction of patient’s
response to treatment with sertraline or placebo.32 In that
study, utilizing an electrochemistry-based analytical platform
that enables quantification of redox active compounds, we
found that metabolites from phenylalanine, tryptophan, purine
and tocopherol pathways enabled separation of responders
and non-responders to treatment with the SSRI or placebo.
The current study extends on these findings by (1) analyzing
different classes of metabolites using GC-TOF mass spectro-
metry analytical platform; (2) identifying the biochemical
changes that occur in MDD patients 1 week and 4 weeks
after treatment with sertraline or placebo, and (3) identifying
which changes are associated with a reduction in depressive
symptoms after 1 and 4 weeks of treatment with sertraline or
placebo.
Several metabolites from multiple pathways were changed
in sertraline- and placebo-treated subjects. In both sertraline-
Table 3 Correlations with treatment outcomes: correlations between biochem-
ical changes and changes in Ham-D
Metabolite Cor P-value
(a) One-week sertraline
5-Methoxytryptamine 0.405 0.016
Arachidonic acid isom 0.398 0.018
Ribose 0.389 0.021
Cystine 0.370 0.029
Trehalose 0.358 0.035
a-Ketoglutaric acid 0.339 0.047
Xylose 0.335 0.049
(b) One-week placebo
Phosphoric acid 0.510 0.001
4-Hydroxyproline 0.439 0.005
Cholesterol 0.397 0.011
Malate 0.323 0.042
(c) Four-week sertraline
Valine 0.507 0.002
Leucine 0.478 0.004
Lactic acid 0.435 0.009
Pseudo uridine 0.409 0.015
Conduritol-b-epoxi 0.406 0.015
Isoleucine 0.382 0.024
Mannonic acid NIST 0.380 0.024
Cystine 0.362 0.032
Inulobiose 0.361 0.033
(d) Four-week placebo
Lactic acid 0.383 0.015
Ribose6 0.371 0.018
3-Hydroxybutanoic acid 0.355 0.025
Oxalic acid 0.346 0.029
Hydroxycarbamate NIST 0.345 0.029
Citrulline 0.336 0.034
Indole-3-acetate 0.323 0.042
1-Monostearin 0.318 0.046
Negative correlations indicate better response with increase in metabolite;
positive indicates better response with decrease in metabolite.
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and placebo-treated patients, the larger effects were
observed after 4 weeks of treatment compared with 1 week.
Multiple mechanisms could account for the biochemical
changes observed in this study. Progression of the disease
itself, as well as behavioral changes (for example, changes in
diet) associated with improvement of the symptoms after
treatment, could explain some of the effects such as changes
in fatty acids and indices of energy metabolism. Thus, it was
suggested that plasma levels of linoleic acid may serve as a
possible biomarker for residual depression and anxiety in
older people with previous depression;40 it was also shown
earlier that increased dietary intake of oleic acid was
associated with reduced risk of severe depressed mood
among women while increased dietary intake of linoleic acid
was associated with increased risk of severe depressedmood
among men.41 It was recently found that omega-3 augmenta-
tion of SSRI citalopram treatment produced a significantly
greater reduction in HAM-D scores compared with citalopram
treatment alone.42 In a yeast model, sertraline has been
shown to inhibit phospholipases A1 and D and activates
phospholipase A2.43 It is thus possible, if the effect on
phospholipases is similar in mammalian systems, that the
changes in fatty acids observed in this study could be the
result of sertraline inhibition and/or activation of specific
phospholipases. It was also shown in primary cultures of
mouse astrocytes that chronic SSRIs treatment upregulates
calcium-dependent phospholipase A2 (PLA2), which releases
arachidonic acid from the membrane-bound phospholi-
pids.44,45 Additional mechanism, involving PLA2 activation
and increased release of arachidonic acid following SSRIs
could involve membrane phospholipids remodeling and
changes in signal transduction pathways.46,47 The changes
noted in fatty acids in the placebo group are of interest and
could reflect changes in fatty acid biosynthesis or degradation
as disease progresses. It can also be common to what was
observed in the sertraline group.
Several studies implicated impairment of energy metabo-
lism pathways in both pathogenesis of depression and effects
of antidepressants. In an animal model of depression, levels
of aconitate hydratase and pyruvate dehydrogenase were
found to be regulated in opposite directions by stress and
antidepressant drug treatment, thus representing molecular
correlates of both vulnerability to depression and response to
drug.48 Chronic administration of different antidepressants,
including SSRIs, was associated with increased levels of
biomarkers for energy metabolism, such as activity of brain
creatine kinase, of mitochondrial respiratory chain complexes
II and IV, and of citrate synthase and succinate dehydrogen-
ase.17,49,50 Recently in an animal model significant changes in
amino-acid metabolism related to energy metabolism via TCA
cycle, and increased levels of glucose, glucose-6-phosphate
and fructose-6-phosphate following chronic paroxetine treat-
ment were found.18 Additional mechanisms related to the
observed changes in energy metabolism following sertraline
treatment could be related to the effects of 5-HT on glucose
metabolism and glycolysis. It was demonstrated that 5-HT
stimulates glucose uptake in skeletal muscle and activates
skeletal muscle 6-phosphofructo-1-kinase activity in a dose-
response through 5-HT2A receptors.51 Recently, it was found
that 5-HT through 5-HT2A receptors controls hepatic
glycolysis in mice,52 and 5-HT had stimulatory and inhibitory
effects on glycogen synthesis in hepatocytes mediated by
5-HT1/2A and 5-HT2B receptors, respectively.53
We also analyzed associations between changes in
individual metabolites and treatment outcome. After 1 week
of sertraline treatment, the decrease in 5-methoxytryptamine
and increases in arachidonic acid and a-ketoglutarate levels
were the most significant in association with symptoms
reduction. Association of decrease in 5-MTPMwith symptoms
reduction suggests potential role of methoxyindole branch of
the tryptophan pathway in recovery form depressed state;
currently we are investigating different branches of the
pathway in the effects of SSRIs. Changes in the levels of
arachidonic levels most likely reflect increase in the activity in
phospholipase A2, resulting from increased 5-HT levels at
earlier time point.44,45 Association of increased levels of a-
ketoglutarate with symptoms reduction is not clear; however,
it may be related to the activation of energy metabolism
following SSRI treatment. In support of this mechanism is the
observation that improvement of symptoms at 4 weeks of
treatment with sertraline was associated with decreased
levels of lactic acid. The most significant changes associated
with symptoms reduction after 4 weeks of treatment with
sertraline were decreases in the levels of BCAAs, valine,
leucine and isoleucine. In our previous study, we have
demonstrated that higher levels of leucine and isoleucine
were associated with depression.29 BCAAs have well-
established anabolic effects on protein metabolism that
involves activation of mTOR pathway. In this respect, it is
particularly interesting that antidepressant effect of NMDA
receptor antagonist ketamine results from activation of mTOR
pathway involving BCAAs.54 In a recent study, Webhofer
et al.18 found that in mice valine, leucine and isoleucine levels
were increased after chronic treatment with SSRI paroxetine.
Detailed mapping of effects of SSRIs, as well as of other
antidepressants, on metabolism in animals and in humans
should be compared at a more detailed level to enable
translational research.
Of interest, there were several metabolites that closely
correlated with changes in BCAAs and these included
methionine and tyrosine. Methionine and the methionine
cycle are closely linked to the folate cycle, to one carbon
metabolism and to methylation processes that have been
implicated in depression.
While there is strong evidence that MDD is influenced by
inheritance,55 GWA studies for possible genetic factors that
contribute to MDD risk, as well as GWA studies for genes
associated with SSRI response in MDD patients, have
provided somewhat disappointing results.56,57 However, it
was demonstrated that the SNP in the ABCB1 gene encoding
ATP-binding cassette, subfamily B (MDR/TAP), member 1
(ABCB1) transporter protein expressed in the endothelial cells
of the blood–brain barrier, is associated with severity of MDD
and its response to citalopram and escitaloppram.58,59
Recently, in GWA study Kohli et al.60 identified the SNP in a
gene encoding a neuron-specific neutral amino-acid trans-
porter, SLC6A15, as an MDD risk gene. While the exact
function of the SLC6A15 SNP is not well understood, from
both human and animal studies, it is known that SLC6A15
belongs to the solute carrier 6 (SLC6) gene family, which also
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includes the transporters for monoamines (including serotonin
transporter, the primary target for SSRIs) and neurotransmit-
ter amino acids, as well as a sodium-dependent transporter
for neutral amino acids, including BCAAs.61 Earlier it was
shown that in the SLC6A15 knockout mice, leucine uptake
into cortical synaptosomes is significantly reduced.62 Zhou
et al.63 demonstrated that SSRIs sertraline and fluoxetine
have high affinity for the prokaryotic leucine transporter
homolog (LeuT) of SLC6A15. Interestingly, SSRIs also bind
to the homologous norepinephrine and dopamine transpor-
ters, although with much lower affinity than to their principal
target serotonin transporter,64,65 and only one or two different
functional group substitutions are sufficient to convert an
SSRI into a norepinephrine reuptake inhibitor with higher
affinity to norepinephrine transporter.66,67 Therefore, it is not
unlikely that observed effect of sertraline on BCAAs could
result from the SLC6A15SNP in depressed patients. All these
findings and the association between the improvement of
depression and changes in BCAAs levels observed in our
study strongly suggest potential role of BCAA in depression
and in the effects of SSRI; further studies are needed to
examine potential role of BCAAs in depression and the effects
of different antidepressants, in both patients and animal
models.
One of the limitations of this study is that despite
comprehensive biochemical analysis it included relatively
small number of subjects. However, this study should be
viewed as hypotheses-generating to test whether metabolo-
mics approach could provide insights into pathways impli-
cated in SSRI and placebo response and mechanism of
delayed response. Replication and validation of these findings
in other clinical trials is important for future studies, however,
this is outside the scope of this first report. Whether and to
what extent peripheral biochemical changes reflect CNS
(central nervous system) changes related to mechanisms of
depression and drug effects also should be addressed in
future studies. Depression is a disease that affects both brain
and also the rest of the body, as is well known from the cortisol
data;68,69 therefore, it is possible that the peripheral changes
reflect both direct CNS and additional CNS-linked peripheral
effects and maybe direct peripheral effects also. Irrespective
of the exact mechanism that leads to the changes and to
response, the presence of consistent changes can be an
important signature that could be the basis of further iterative
understanding from both animal and human studies.
In conclusion, our data for the first time illustrate that
biochemical changes following SSRI treatment are progres-
sive and some of the pathways that are modified in the first
weekmight lead to subsequent changes noted in the following
weeks. The presence of consistent changes could provide an
opportunity for developing biomarkers that can predict
response or no response to antidepressant treatment.
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